mnda motor neurone disease association

36th international symposium on ALS/MND

36th international symposium on ALS/MND

5-7 December 2025
San Diego, USA

ALS ASSOCIATION

Host: ALS Association

Organised by the Motor Neurone Disease Association of England, Wales and Northern Ireland

PROGRAMME

36th international symposium on ALS/MND

Organiser of the Symposium

mnda motor neurone disease association

Motor Neurone Disease Association

Francis Crick House
6 Summerhouse Road
Moulton Park, Northampton NN3 6BJ

Tel: +44 1604 250505

Email: symposium@mndassociation.org

www.symposium.mndassociation.org

Host for the Symposium

ALS ASSOCIATION

ALS Association

1300 Wilson Boulevard, Suite 600
Arlington, VA 22209, USA

Tel: (1) 800 782 4747

Email: alsinfo@als.org

www.als.org

CPD/CME Accreditation

The 36th International Symposium on ALS/MND has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credit(s).

Welcome

Dear Friends, Colleagues, and Members of the ALS Community

It is my great honor to welcome you to the 36th Annual International Symposium on ALS/MND. This event brings together researchers, doctors, people living with ALS, caregivers, and advocates from all around the world. Though we all come from different places and roles, we share one urgent mission: to end ALS.

This year's program is both exciting and hopeful. Over the next three days, we'll explore many promising areas—from new ideas in genetics and stem cell research, to advances in technology, nutrition, and breathing support that can make a real difference in quality of life. We'll also learn how tools like artificial intelligence are helping us uncover new insights faster than ever before.

I also want to take a moment to thank the people who make this gathering possible: the organizers, presenters, sponsors, and all of you who contribute your time, knowledge, and energy. Your dedication ensures that this symposium remains a very important global meeting place for ALS research and care.

As you join the sessions, workshops, and conversations, I encourage you to be curious, to share ideas openly, and to build connections that will spark the progress of tomorrow. This symposium is about more than sharing results - it's about working together to move faster and to make a greater impact.

On behalf of the ALS Association, thank you for being here and for being part of this vital work.

Sincerely,
Calaneet Balas
CEO, ALS Association

Foreword

Welcome to the 36th International Symposium on ALS/MND. For the eighth time, the symposium is taking place in the USA. Following successful meetings in Boston (28th symposium in 2017), Chicago (23rd and 7th symposia in 2012 and 1996), Orlando (26th and 21st symposia in 2015 and 2010), Philadelphia (15th symposium in 2004) and Oakland (12th symposium in 2001) this is the first time it will be held in San Diego. It was originally planned for 2020, but delayed because of the pandemic, and now at last, we will have the chance to explore all this vibrant coastal city has to offer, in person.

San Diego is the eighth most populous city in the US and is famous for its beaches, parks and warm climate. It has a reputation for being laid back but also hosts multiple Michelin starred restaurants, the immense Balboa Park, an active naval fleet and the USS Midway aircraft carrier, now a museum. San Diego scientists and inventors have developed some of the most important advances in the history of medicine. It was here that the Salk vaccine was developed in the 1950s, preventing the devastating infectious motor neuron disease, polio, and heralding routine childhood vaccination programmes. More recently, San Diego has been the pioneering hub of the use of antisense oligonucleotides as a therapy for ALS/MND, the first treatment to make a proper dent in the natural history of this condition. We can also learn a lot from the general culture here. The School of Medicine at University of California San Diego began in 1968 with a very unconventional approach, having no traditional science departments and instead focusing on cross-campus collaboration and unique projects. The spirit of this multidisciplinary, multicentre approach to science is particularly pertinent today in ALS, as we combine skills and expertise across continents and specialities to accelerate the search for a cure.

San Diego is reputed to have the number one zoo in the world, known for its lush, natural habitats, related botanical gardens, and very rare animal species. Like the zoo, this year's symposium (number one in the world of ALS/MND) has its natural themes of epidemiology, genomics, cell and disease models, proteomics, trials, biomarkers and neurophysiology, its related fields of RNA biology, and ALS-FTD pathogenesis, and the rare, emerging and increasingly important themes of FUS pathology and therapy, primary lateral sclerosis, and preclinical ALS. These topics are advancing rapidly and strongly, across our global community, translating directly into new therapies to be trialled more rapidly than ever before. The symposium brings us the inspiration, knowledge and vision to carry us forward through the next year. I wish you all a very informative and enjoyable meeting.

Ammar Al-Chalabi
Programme Committee Chair

Friday 5 December

SESSION 1

JOINT OPENING SESSION

LIVE STREAM SESSION

Location: Commodore A-D

Chairs: A Al-Chalabi (UK), B Dickie (UK)

08.30 – 08.35
Welcome
A Al-Chalabi (UK) and B Dickie (UK)

08.35 – 08.45
Welcome from The ALS Association
C Balas (USA)

08.45 – 09.25
C1 Stephen Hawking Memorial Lecture:
Space-induced human neural senescence
A Muotri (USA)

09.25 – 09.45
International Alliance Forbes Norris Award

09.45 – 10.00
IPG Award and winner's research presentation

10.00 – 10.30 **REFRESHMENTS AND NETWORKING:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**
EXHIBITORS: **Commodore Foyer**

SESSION 2A

MODELLING AND TREATING ALS WITH STEM CELLS

LIVE STREAM SESSION

Location: Commodore A-D

Chairs: C Svendsen (USA), M Cudkowicz (USA)

10.30 – 11.00
C2 Modelling and treating ALS with stem cells:
Introduction - Opportunities and challenges
C Svendsen (USA) M Cudkowicz (USA)

11.00 – 11.20
Lessons learned from therapeutic stem cell trials
J Glass (USA)

11.20 – 11.40
Use of advanced CRISPR technologies in iPSC modelling
C Clelland (USA)

11.40 – 12.00
Organoid and assembloid models to study neurodegenerative disease
J Andersen (USA)

12.00 – 12.30
DISCUSSION

SESSION 2B

GENES AND PHENOTYES

Location: Constellation

Chairs: P Andersen (Sweden), M van Es (Netherlands)

10.30 – 11.15
C3 Understanding ALS in Latin America: Insights into Genetic Diversity, Phenotypic Heterogeneity, and Emerging Opportunities
JM Matamala (Chile), M Franca (Brazil)

11.15 – 11.30
C4 Penetrance of neurodegenerative disorders in families carrying C9orf72 repeat expansions
A Douglas (UK)

11.30 – 11.45
C5 Phenome-wide association study of C9orf72 pathogenic repeat expansions using ICD-10 diagnosis codes in the UK Biobank
A Soma (UK)

11.45 – 12.00
C6 Short tandem repeat expansions as genetic risk factors and disease modifiers in ALS
K-Y Jih (Taiwan)

12.00 – 12.15
C7 Incidence of neurodegenerative diseases in c9orf72 expansion carriers is influenced by UNC13A genotype
A Thompson (UK)

12.15 – 12.30
C8 Genotype-phenotype analysis of TARDBP p.M337V in a large Chinese ALS family: An 18-year follow up story
M Deng (China)

12.30 – 14.00 **LUNCH:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**

SESSION 3A

GENETICS AND GENOMICS

Location: Commodore A-D

Chairs: M Harms (USA), A Iacoangeli (UK)

14.00 – 14.15
C9 A new cause of familial ALS: Loss of function of DNAJC7 impairs TDP-43 regulation
T Yamashita (Japan)

14.15 – 14.30
C10 Large-scale exome analysis reveals novel rare variant contributions to ALS and identifies YKT6 and ARPP21 as risk genes
K Kenna (Netherlands)

14.30 – 14.45
C11 Characterization and functional evaluation of RNA- driven gene fusions in ALS
A Boudi (USA)

14.45 – 15.00
C12 Developmental, oxidative stress-associated clonal somatic mutations in sporadic ALS
H Kim (South Korea)

15.00 – 15.15
C13 Recurrent patterns of widespread neuronal genomic damage shared by major neurodegenerative disorders
Z Zhou (USA)

15.15 – 15.30
C14 Unravelling TDP-43 pathology in ALS: A spatially resolved multiomics approach
Z Butti (USA)

SESSION 3B

LIVE STREAM SESSION

CLINICAL TRIALS AND TRIAL DESIGN

Location: Constellation

Chairs: R van Eijk (Netherlands), J Berry (USA)

14.00 – 14.15
C15 DNL343 in ALS: Results from the double-blind placebo-controlled, randomized HEALEY ALS Platform Trial
S Babu (USA)

14.15 – 14.30
C16 Clinical results of a Phase 2a trial evaluating the synaptogenic small molecule SPG302 in ALS participants
D Rowe (Australia)

14.30 – 14.45
C17 Top line results of the Phase 2 proof-of-concept study of AP-101, a first in class human antibody targeting misfolded SOD1 in ALS
A Genge (Canada)

14.45 – 15.00
C18 From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 clinical and biomarker insights into a global Phase 3 trial
M Cudkowicz (USA)

15.00 – 15.15
C19 Top line results of the Phase 1b, open label, multiple ascending dose study of VRG50635 in participants with familial and sporadic ALS
L van den Berg (Netherlands)

15.15 – 15.35
C20 Advances in SMA treatment: Lessons for ALS
C Sumner (USA)

15.30 – 16.00 **REFRESHMENTS AND NETWORKING:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**
EXHIBITORS: **Commodore Foyer**

SESSION 4A

CELL AND ORGANELLE ANALYSES

LIVE STREAM SESSION

Location: Commodore A-D

Chairs: J Ravits (USA), C Vande Velde (Canada)

16.00 – 16.30
C21 Imaging protein aggregation in neurodegenerative disease
D Klenerman (UK)

16.30 – 17.00
C22 Organellomics: AI-driven deep organelle phenotyping uncovers novel ALS mechanisms in motor neurons
E Hornstein (Israel)

17.00 – 17.15
C23 Project Genesis: A program on the origins of sporadic ALS. Nucleoporin coding variants cause altered nuclear pore structure, function, downstream TDP-43 dysfunction and neurodegeneration in sporadic ALS
J Rothstein (USA)

17.15 – 17.30
C24 Novel cell specific insights from single-cell multiome profiling of diseased and healthy motor cortex
J Cooper-Knock (UK)

SESSION 4B

CLINICAL ELECTROPHYSIOLOGY AND IMAGING

Location: Constellation

Chairs: H-J Westeneng (Netherlands), E Pioro (Canada)

16.00 – 16.30
C25 ALS through a physiologist's prism: Possible contributions of motor neuron circuit pathophysiology
R Brownstone (UK)

16.30 – 16.45
C26 Spinal motoneuron excitability as a marker of upper motor neuron dysfunction in Primary Lateral Sclerosis
M Oliveira Santos (Portugal)

16.45 – 17.00
C27 Application of automated brain segmentation software (Quantib) in a cohort of patients affected by amyotrophic lateral sclerosis
A Doretti (Italy)

17.00 – 17.15
C28 ALS cervical cord MRI metanalysis shows flattening of the cervical enlargement region
T Yazdanian (USA)

17.15 – 17.30
C29 Multiparametric MRI neuroimaging reveals widespread brain alterations in ALS beyond the motor cortex
M Bafrani (USA), S Ghaderi (Iran)

POSTER SESSION A 17.30 – 19.00

Location: Bay Pavilion

Theme 1	Epidemiology and informatics
Theme 2	Genetics and genomics
Theme 4	In vivo experimental models
Theme 7	Pre-clinical therapeutic strategies
Theme 9	Clinical trials and trial design
Theme 11	Cognitive and psychological assessment and support
WIP-CP	Care practice work in progress



SESSION 5A

EPIGENETICS, AGING AND SELECTIVE VULNERABILITY

Location: Commodore A-D

Chairs: J Robertson (Canada), T Shelkovnikova (UK)

08.30 – 09.00
C30 The genome and its memory: Epigenetic studies of ALS and related diseases
E Rogaeva (Canada)

09.00 – 09.15
C31 Integrated transcriptomic and epigenetic profiling in ALS motor neurons using ONT direct RNA and DNA sequencing
J Melki (Australia)

09.15 – 09.30
C32 Neuronal aging leads to mislocalization of TDP-43
K Rhine (USA)

09.30 – 09.45
C33 Regional susceptibility to TDP-43 pathology is driven independently by age and disease specific factors
H Spence (UK)

09.45 – 10.00
C34 Adenosine deaminase loss leads to purine metabolism dysfunction, senescence and reduced DNA repair mechanisms in sALS astrocytes
S Allen (UK)

SESSION 5B

COGNITIVE AND PSYCHOLOGICAL ASSESSMENT AND SUPPORT

Location: Constellation

Chairs: C Lomen-Hoerth (USA), S Abrahams (UK)

08.30 – 09.00
C35 Clinical management and cognitive testing in ALS and Frontotemporal Spectrum Disorder
C Lomen-Hoerth (USA)

09.00 – 09.20
C36 Survival, cognitive and behavioural impairment in ALS
R Radakovic (UK)

09.20 – 09.40
C37 Characterising behavioural symptoms in ALS: The ECAS Extended Behaviour interview
C McHutchinson (UK)

09.40 – 10.00
C38 Exploring the role of relationship closeness in the association between behavioural symptoms and carers' anticipatory grief in MND
A Trucco (UK)

SESSION 5C

LIVE STREAM SESSION

PRIMARY LATERAL SCLEROSIS

Location: Commodore E

Chairs: S Paganoni (USA), A Genge (Canada)

08.30 – 08.40
C39 Progress in primary lateral sclerosis (PLS) research: Introduction S Paganoni (USA)
H Mitsumoto (USA)

08.40 – 08.50
Understanding the cellular and molecular basis of upper motor neuron degeneration
H Ozdinler (USA)

08.50 – 09.00
In-depth profiling of PLS and related disorders
A Jain (USA)

09.00 – 09.10
Longitudinal changes in motor and cognitive/behavioural function in PLS: Insights from the CReATe Consortium's Phenotype-Genotype-Biomarker Study
M Benatar (USA)

09.10 – 09.20
Startle reflex in primary lateral sclerosis: A comparison with amyotrophic lateral sclerosis
G Jang (USA)

09.20 – 09.30
Implications for diagnostic criteria from a Natural History Study in the Netherlands
M Van Es (Netherlands)

09:30 – 09:40
Natural History Study: PLSFRS and other outcomes assessments
I Lee (USA)

09.40 – 10.00
Discussion and final announcements

10.00 – 10.30 **REFRESHMENTS AND NETWORKING:** Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer
EXHIBITORS: Commodore Foyer

SESSION 6A

PROTEOSTASIS & PROTEOTOXICITY

Location: Commodore A-D

Chairs: R Sattler (USA), K Talbot (UK)

10.30 – 11.00
C40 A potential therapeutic strategy for ALS and other TDP-43 proteinopathies
D Cleveland (USA)

11.00 – 11.15
C41 AP21A and the autophagy pathway modify TDP-43 toxicity
A Held (USA)

11.15 – 11.30
C42 A disease-responsive modified cyclin F gene therapy for clearance of cytoplasmic TDP-43
J Davidson (Australia)

11.30 – 11.45
C43 TDP-43 oligomer-specific antibody detects misfolded TDP-43 in ALS and rescues phenotype in ALS iPSC-derived neurons and mouse models
Y-R Chen (Taiwan)

11.45 – 12.00
C44 Novel TDP-43 aptamers identify early aggregation events in C9orf72 mutant human motor neurons
O Taso (UK)

12.00 – 12.15
C45 Mutation-dependent stress pathway activation in ALS: Insights from VAPB P56S motor neurons
H Miranda (USA)

12.15 – 12.30
C46 Macrophage migration inhibitory factor (MIF) as a potential therapeutic target for ALS
A Israelson (Israel)

SESSION 6B

BIOMARKERS

Location: Constellation

Chairs: M Basso (Italy), M Turner (UK)

10.30 – 10.50
C47 Proteomic analysis of cerebrospinal fluid identifies two distinct molecular subtypes in ALS
P Lingor (Germany)

10.50 – 11.10
C48 Characterising the CSF biomarker signature of Calpain-2 activity in ALS and the biomarker impact of Calpain-2 inhibition in a preclinical model of ALS
R Bowser (USA)

11.10 – 11.30
C49 A blood test to monitor TDP-43 dysfunction for ALS
P Wong (USA)

11.30 – 11.45
C50 Blood-derived miRNA signature accurately diagnoses ALS
R Dunlop (USA)

11.45 – 12.00
C51 Combination of serum neurofilament light chain and cardiac troponin T as biomarkers improves diagnostic accuracy in ALS
P Lindenborn Germany)

12.00 – 12.15
C52 Neurodegeneration NULISA panel in ALS patients and presymptomatic subjects reveals potential diagnostic and prognostic biomarkers: A premodiALS study
L Tzeplaeff (Germany)

12.15 – 12.30
C53 Skin as a window to central TDP-43 pathology in ALS
K Hanna (UK)

SESSION 6C

LIVE STREAM SESSION

EPIDEMIOLOGY

Location: Commodore E

Chairs: A Chiò (Italy), J Cooper-Knock (UK)

10.30 – 10.50
C54 The incidence and prevalence of ALS among people with diabetes mellitus are increasing in the United States
X Song (USA)

10.50 – 11.10
C55 Association of military branch and rank with ALS incidence among United States veterans
M Weisskopf (USA)

11.10 – 11.30
C56 How pre-diagnosis comorbidities shape ALS prognosis in a large Chinese cohort
M Deng (China)

11.30 – 11.50
C57 Extreme exercise in males is linked to onset of ALS in C9orf72
G Erdi-Krausz (UK)

11.50 – 12.10
C58 Another brick in our knowledge of ALS causes: A population-based study of residential clustering
A Calvo (Italy)

12.10 – 12.30
C59 The International ALS/MND Natural History Consortium: Co- ordination, data quality, compliance, sustainability and sharing
A Sherman (USA)

12.30 – 14.00 LUNCH: Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer

SESSION 7A

RNA BIOLOGY

Location: Commodore A-D

Chairs: J Rothstein (USA), D Zarnescu (USA)

14.00 – 14.30
C60 Regulation of RNA processing in neuronal health, aging and disease
G Yeo (USA)

14.30 – 14.45
C61 RNA-binding protein mislocalization in ALS and FTLD
A Breevoort (USA)

14.45 – 15.00
C62 Elucidating the pathological interplay between cytoskeletal alterations and mRNA metabolism in Profilin 1-mutant human motor neurons
C Steffke (Germany)

15.00 – 15.15
C63 The ribonucleoprotein complex of ALS-associated circular RNA hsa_circ_0000119 harbors key proteins linked to ALS pathophysiology
K Smith (USA)

15.15 – 15.30
C64 TYK2 mediates neuroinflammation in brains with cytoplasmic dsRNA co-inciding with TDP-43 pathology: A common therapeutic approach for neurodegenerative diseases
L König (USA)

SESSION 7B

LIVE STREAM SESSION

ALS-FTD PATHOGENESIS

Location: Constellation

Chairs: A La Spada (USA), S Pozzi (Canada)

14.00 – 14.30
C65 FTD/ALS pathogenesis: swimming upstream
W Seeley (USA)

14.30 – 15.00
C66 Contribution of C9orf72 loss of function to ALS and FTD
J Robertson (Canada)

15.00 – 15.15
C67 TDP-43 toxic gain of function links ALS, FTD and Alzheimer's disease through splicing dysregulation
W Van Zuiden (Israel)

15.15 – 15.30
C68 Contribution of Alzheimer's disease co-pathology to cognitive impairment in ALS: Evidence from cerebrospinal fluid, blood plasma and autopsy data
E Kasper (Germany)

SESSION 7C

NUTRITIONAL & RESPIRATORY MANAGEMENT

Location: Commodore E

Chairs: G Pattee (USA), C McDermott (UK)

14.00 – 14.20
C69 Optimised machine learning for time-to-event prediction in healthcare applied to timing of gastrostomy in ALS: A multi- centre, retrospective model development and validation study
M Weinreich (UK)

14.20 – 14.40
C70 Weight trajectories and survival following PEG insertion in patients with MND at a single site university affiliated hospital: A retrospective cohort study
M Joyce (Australia)

14.40 – 15.00
C71 Prevalence and clinical relevance of gastrointestinal symptoms in ALS: A prospective observational study
J Lops (Italy)

15.00 – 15.15
C72 Oral Secretion Scale: A multi-national validated clinimetric scale for assessing state of secretion management in NIV-treated ALS patients identifies differences in secretion management device and medication use according to site of onset
P Cazzolli (USA)

15.15 – 15.30
C73 Deep learning-derived chest CT metrics predict disease progression and survival in ALS
J Kim (South Korea)

15.30 – 16.00 **REFRESHMENTS AND NETWORKING:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**
EXHIBITORS: **Commodore Foyer**

SESSION 8A

DISEASE MODELS

Location: Commodore A-D

Chairs: H Inoue (Japan), P Noakes (Australia)

16.00 – 16.20
C74 An elongator mouse model of ALS spotlights TDP-43 in the motor neuron nucleolus
L George (USA)

16.20 – 16.40
C75 C9orf72 dipeptide repeat proteins affect spinal motor neuron selective vulnerability and impact neuronal plasticity in knock-in mouse models
C Milioto (UK)

16.40 – 17.00
C76 Neuronal targeted Caveolin-1 overexpression preserves mitochondrial integrity and cognitive function in a TDP-43 mouse model of ALS/FTD
V Ta (USA)

17.00 – 17.15
C77 Deciphering metabolic dysregulation at the synapse in drosophila models of ALS
S Langberg (USA)

17.15 – 17.30
C78 Novel strategies to prevent aberrant central motor synapse elimination in ALS-FTD
M Van Campenhoudt (Switzerland)

SESSION 8B

LIVE STREAM SESSION

PRECLINICAL AND PRODROMAL ALS

Location: Constellation

Chairs: P Lingor (Germany), A Thompson (UK)

16.00 – 16.15
C79 Applying machine learning in predictive multiomics reveals biomarkers of an ALS prodrome
A Strange (UK)

16.15 – 16.30
C80 Spatial transcriptomics identifies distinct peripheral immune signatures in pre-symptomatic ALS
J Gregory (UK)

16.30 – 16.45
C81 ALS and FTD have distinct prediagnostic blood biochemical profiles
C Chalitsios (UK)

16.45 – 17.00
C82 Predicting phenoconversion to clinically manifest disease: results of a large-scale proteomic study
M Benatar (USA)

17.00 – 17.15
C83 Higher blood total cholesterol, LDL-c and HDL-c all associated with increased risk of ALS up to ten years prior to diagnosis: A nationwide multiple registry case- control study
J Storgaard (Denmark)

17.15 – 17.30
C84 Hypermetabolism is common among symptomatic and asymptomatic C9orf72 pathogenic variant carriers and is associated with elevated neurofilament light chain levels
I Lee (USA)

SESSION 8C

IMPROVING CLINICAL DECISION MAKING: RESEARCH, POLICY AND PRACTICE

Location: Commodore E

Chairs: S Babu (USA), T Meyer (Germany)

16.00 – 16.15
C85 Oligogenic risk and emerging genetic modifiers: Hot topics in genetic counselling and testing for ALS/FTD
K Salmon (Canada), L Dratch (USA)

16.15 – 16.30
C86 ALS VUS Second Opinion Service (VUS SOS): assisting the world's clinicians with VUS annotations and interpretation
M Harms (USA)

16.30 – 16.45
C87 Red Flags for ALS referral: Insights from the Turin ALS Expert Center
A Chiò (Italy)

16.45 – 17.00
C88 Characteristics and early diagnosis on MND in 67 million individuals in England: A comparative study on phenotyping models derived by AI, Knowledge Graph and the MND Association Red Flags tool
Y Abdulle (UK)

17.00 – 17.15
C89 Remote speech-derived biomarkers enable sensitive and feasible longitudinal monitoring of ALS progression
A König (Germany)

17.15 – 17.30
C90 Early prediction of bulbar decline in ALS using remotely-collected objective speech measures: A Kaplan-Meier time-to-event analysis
D Suendermann-Oeft (USA)

POSTER SESSION B 17.30 – 19.00

Location: Bay Pavilion

Theme 3	In vitro experimental models
Theme 5	Human cell biology and pathology (including iPSC studies)
Theme 6	Tissue biomarkers
Theme 8	Clinical imaging and electrophysiology
Theme 10	Disease stratification and phenotyping of patients
Theme 12	Clinical management and support
WIP-BM	Biomedical work in progress

POSTER SESSION C 08.30 – 10.00

Location: Bay Pavilion

No presentations scheduled; delegates are welcome to view the poster hall

10.00 – 10.30 **REFRESHMENTS AND NETWORKING:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**
EXHIBITORS: **Commodore Foyer**

SESSION 9A

FUS ALS

Location: Commodore A-D

Chairs: J Gregory (UK), J Prehn (Ireland)

10.30 – 10.50
C91 Dissecting the role of skeletal muscle in FUS-associated ALS
H Walgrave (Netherlands)

10.50 – 11.10
C92 RNA aptamers enable selective detection of FUS pathology in ALS
F Waldron (UK)

11.10 – 11.30
C93 Targeting aberrant FUS intron retention in ALS
Y Wang (UK)

11.30 – 11.50
C94 M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development
T Shelkovnikova (UK)

11.50 – 12.10
C95 Identifying FUS-like sporadic ALS patients through molecular phenotypic profiling
S Altschuler (USA)

12.10 – 12.30
C96 Longitudinal profiling of transcriptomic and proteomic changes in biofluids of FUS-ALS patients treated with FUS antisense oligonucleotide
O Rifai (USA)

SESSION 9B

THERAPEUTIC STRATEGIES

LIVE STREAM SESSION

Location: Constellation

Chairs: F Jeganathan (UK), D Rowe (Australia)

10.30 – 11.00
C97 Machine learning enabled ALS target and therapeutic discovery
S Sances (USA)

11.00 – 11.15
C98 Development of ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, for the treatment of ALS
K Church (USA)

11.15 – 11.30
C99 Development of a novel brain-penetrant small molecule for rectifying TDP-43 dysfunction in ALS
A Berson (USA)

11.30 – 11.45
C100 Development of LTX-002, a novel ASO for the treatment of ALS
L Heckman (USA)

11.45 – 12.00
C101 Nonclinical studies supporting the clinical development of the antisense oligonucleotide TRCN- 1023 to restore UNC13A protein and function in people living with ALS
I Antonijevic (USA)

12.00 – 12.15
C102 AAV-delivered Anti-PC-OxPL antibody fragments: A novel therapeutic strategy targeting ALS pathology
A Duarte (USA)

12.15 – 12.30
C103 Impact of intrathecal delivery of INS1202 AAV9-SOD1-shRNA on hallmarks of neurodegeneration in a murine disease model of ALS and patient-derived in vitro models
L Ferraiuolo (USA)

SESSION 9C

ASSISTIVE TECHNOLOGY

THIS SESSION IS NOT ELIGIBLE FOR CPD CREDITS

Location: Commodore E

Chairs: K Dave (USA), J Bedford (UK)

10.30 – 10.40
INTRODUCTION
K Dave (USA)

10.40 – 11.10
C104 Enhancing quality of life through insights based on the ALS/MND Personal Needs Matrix
J Chudge (UK)

11.10 – 11.40
C105 Transforming communications for ALS patients: Clinical Validation of an AI-powered augmented reality brain-computer Interface
C Ullrich (USA)

11.40 – 12.10
C106 The Triple 'A' Framework: Expanding access to AAC for people with ALS/MND
J Schorey (USA)

12.10 – 12.30
DISCUSSION

12.30 – 13.30 **LUNCH:** **Commodore Foyer and Terrace, Bay Terrace, Constellation Foyer**

SESSION 10

JOINT CLOSING SESSION

LIVE STREAM SESSION

Location: Commodore A-D

Chairs: A Al-Chalabi (UK), L van den Berg (Netherlands)

13.30 – 13.40
Invitation to Amsterdam 2026

13.40 – 13.50
Poster Prize Awards

13.50 – 14.00
Sean M. Healey International Prize for Innovation in ALS

14.00 – 14.10
Drs. Ayeez and Shelena Lalji & Family
ALS Endowed Award for Innovative Healing

14.10 – 14.40
C107 Phenotypic heterogeneity and ALS/MND subtypes: Potential impact on ALS research and clinical trial design
J Rosenfeld (USA)

14.40 – 15.00
Beyond Barriers: A future where humanity and technology are seamlessly connected
S Gleason (USA)

15.00 – 15.10
Late breaking news

THEME 01
Epidemiology and Informatics

EPI-01 A two-fold increase in motor neuron disease mortality in Australia from 1986 to 2023
Dr Carol Lee

EPI-02 Racial Disparities in ALS Diagnostic Delay: A Comparison Between Illinois and California
Ms. Reshma Kolala

EPI-03 ALS/MND and Military Service: a literature review
Mrs Mandi Bailey

EPI-04 Ambient air pollution and ALS: Evidence from the UK Biobank study
Dr Christos Chalitsios

EPI-05 Investigating the Intersection of Sex and Aging in ALS through Multi-Omics Integration
Dr Mariah Hoffman

EPI-06 Clinical and genetic comparison of ALS patients in Colombia and Spain: Insights from a multicentric epidemiological study
Dr Alejandro Caravaca Puchades

EPI-07 Time-to-event analysis of clinical milestones in the ALS/MND Natural History Consortium Dataset
Dr Kelly Duffy

EPI-08 Differential impact of riluzole use on incident versus prevalent cases in the ALS/MND Natural History Consortium Dataset
Dr Kelly Duffy

EPI-09 Real-world data on disease-modifying drugs for ALS in Japan
Dr Mieko Ogino

EPI-10 Monoclonal Gammopathy and Motor Neuron Disease: A Case Series on Clinical Implications and Treatment Outcomes
Dr Ki-wook Oh

EPI-11 Neurofilament light chain fluctuations during the course of ALS suggest repeat measurements to optimize analysis
Prof. Thomas Meyer

EPI-12 ALL ALS Consortium: A Centralized Participant-Interest Form and Patient Navigation Workflow to Increase Recruitment and Remote Participation
Ms Emma Allen

EPI-13 CONNECT Pilot Program: Developing a Framework for Site-Led Outreach within the ALL ALS Consortium
Dr Emma Goldberg

EPI-14 Research-Ready Electronic Health Records: A Reproducible Pipeline for the ARC Natural History Study
Dr Danielle Boyce

THEME 02
Genetics and Genomics

GEN-01 Single centre incidence in Australia of genetic causes in presumed sporadic ALS
Dr Willem Jan Fokkink

GEN-02 Clinical and genetic characteristics of sporadic ALS in Norway
Miss Camilla Novy

GEN-03 Genetic Landscape of ALS in Korean Patients: Findings from a 10-Year Cohort Analysis
Professor Wonjae Sung

GEN-04 The genetic landscape of ALS in a multi-ethnic population in Israel and development of a personalized diagnostic algorithm based on ethnicity
Professor Vivian Drory

GEN-05 Mapping of relatedness in Norwegian ALS cohort
Mrs Maria Fahlström

GEN-06 Validation of identity-by-descent tools applied to whole exome and whole genome sequencing data from a Norwegian SOD1-family
Mrs Maria Fahlström

GEN-07 Genetic analysis of SOD1 and C9orf72 in a Spanish cohort of ALS patients
Dr Alberto García Redondo

GEN-08 SOD1 variants in Korean patients with MND
Dr Youngkyung Lee

GEN-09 Functional Progression and Clinical-Genetic Description in a Colombian ALS Cohort with SOD1 Variants: A Retrospective Study
Dr Martha Peña Preciado

GEN-10 Targeted long read sequencing to investigate somatic instability of short tandem repeats in C9orf72 expansion carriers
Dr Beatrix Cardus

GEN-11 Clinical Implications of Variants of Uncertain Significance Identified by Multi-Gene Panel in Korean Patients with Amyotrophic Lateral Sclerosis
Ms Jin-ah Kim

GEN-12 Comprehensively profiling the motor phenotypic spectrum of ALS: PLS and PMA
Dr Angita Jain

GEN-13 Identifying genetic risk factors for the development of motor features in patients with Frontotemporal Lobar Degeneration
Dr Ramita Karra

GEN-14 Role of Allelic Variants in HLA Genes as Modifying Factors for Age of Onset in Spanish ALS Patients
Mr Daniel Sanchez-Tejerina

GEN-15 Exploring Genetic Biomarkers in a Spanish Cohort: Analysis of 13 Modifying Variants in ALS Progression and Risk
Mr Daniel Sanchez-Tejerina

GEN-16 Repeat Expansions as Modifiers of Survival in ALS: A Study of Extreme Survivors
Prof. Alfredo Iacoangeli

GEN-17 Heterogeneity and Disease-Associated Changes of Spinal Fibroblasts in Amyotrophic Lateral Sclerosis
Mr Kuo Liao

GEN-18 High-content CRISPR screening in human motor neurons identifies candidate modulators of TDP-43 pathology
Miss Tania Atienzar

GEN-19 Comprehensive mRNA translation measurements reveal sex-specific regulation governed by RNA-binding proteins in ALS
Dr Orel Mizrahi

GEN-20 The landscape of non-reference SINE-VNTR-Alus in amyotrophic lateral sclerosis
Professor Sulev Koks

GEN-21 The impact of CYP2D6 variants on Amyotrophic Lateral Sclerosis risk and survival: a pharmacogenetic analysis
Miss Johanna Kristiina Vallikivi

GEN-22 POSTER WITHDRAWN

GEN-23 Inferring causal effects of CSF and plasma proteins in ALS
Dr Yunfeng Huang

GEN-24 Comprehensive Profiling and Collaborative Integration to Unveil ALS Mechanisms
Ms Terri Thompson

THEME 03
In vitro Experimental Models

IVT-01 Loss-of-function and toxic gain-of-function of TDP43 in an in vitro model of amyotrophic lateral sclerosis.
Dr Alexandre Henriques

IVT-02 Modelling TDP-43 pathology in human oligodendrocytes reveals impaired maturation and myelin gene expression
Miss Tania Atienzar

IVT-03 Extracellular TDP-43 activates the cGAS-STING pathway and AIM2 inflammasome in macrophage
Mr Jae Jun Ban

IVT-04 Correcting TDP-43 Mislocalization in ALS Motor Neurons: A New Mechanistic Insight Into Edaravone Action
Mrs Satsuki Mikuriya

IVT-05 Comparative analysis of in-vitro systems for TDP-43 pathology
Dr Irantzu Perez-Ruiz

IVT-06 Ex vivo characterization of microglial and astrocytic responses to LPS in SOD1 ALS mice primary cells
Dr Irantzu Perez-Ruiz

IVT-07 Nuclear Localization of Mutant SOD1 Disrupts RNA Processing and Induces Type I Interferon Responses in ALS
Dr Yasuhiro Watanabe

IVT-08 Astrocytes control motor neuronal mitochondrial axonal transport deficits in C9ORF72 ALS.
Dr Maria Stavrou

IVT-09 Zinc dysregulation as a potential mechanism in BMAA-linked ALS pathogenesis
Ms Heung-Won Kang

IVT-10 Novel substrate identification of the ALS-FTD associated kinase TBK1
Mr Gabriel Morel

IVT-11 Novel strategies to prevent DNA damage and enhance DNA repair in Amyotrophic Lateral Sclerosis
Ms Fabiha Farzana

IVT-12 Broad phenotypic pathway discovery in motor neurons for Motor Neuron Diseases (MND) therapeutic development
Mr Finbar Gaffey

IVT-13 Investigating a muscle-mediated mechanisms of neuromuscular denervation in ALS
Miss Marion Boyer

IVT-14 Evidence for presynaptic dysfunction in C9orf72 ALS/FTD patient iPSC-derived neurons
Siddhant Suri Dhawan

IVT-15 Early primary-cilium defects in C9orf72 ALS revealed by high-purity iPSC-derived motor neurons
Dr Alba Sansa

IVT-16 Temporal modulation of Polycomb Repressive Complex-2 accelerates maturation of iPSC-derived motor neurons and enhances C9orf72-ALS modeling
Dr Brijesh Singh

IVT-17 Generation of Region-Specific Human iPSC-derived Motor Neurons (iMNs) to Model Regional Vulnerability in ALS
Mr Ken Ning

IVT-18 Characterization of Human iPSC-Derived Motor Neuron Disease Model for ALS Drug Discovery
Mrs Sapna Vyas

IVT-19 Characterisation of a reproducible in vitro motor neuron model for drug discovery in motor neuron disease
Dr Raquel Rua Martins

IVT-20 A Robust Patient-Derived Induced Motor Neuron Platform for High-Throughput ALS Drug Screening
Dr Rafael Renteria

IVT-21 High-Density Microelectrode Arrays (HD-MEAs) for modeling, phenotyping, and screening in ALS and FTD
Dr Marian Hruska-Plochan

IVT-22 POSTER WITHDRAWN

THEME 04
In vivo Experimental Models

IVV-01 Investigation of genome engineered humanized ALS/FTD Drosophila models
Dr Chiara Paolantoni

IVV-02 Sulfated Disaccharide Protects Membrane and DNA Damages from Helical Arginine-rich Dipeptide Repeats in ALS
Dr Yu-Jen Chang

IVV-03 RAN translation of C9orf72-related dipeptide repeat proteins in zebrafish recapitulates hallmarks of amyotrophic lateral sclerosis and identifies hypothermia as a therapeutic strategy
Dr David Burrows

IVV-04 Advancing Disease Monitoring of ALS Zebrafish with the Compound Muscle Action Potential Scan
Dr Anjali Nath

IVV-05 Contribution of KIF5A phase-separation behavior to amyotrophic lateral sclerosis (ALS)
Mrs Valérie Bercier

IVV-06 Ataxin-3 as a regulator of RNA-binding proteins in ALS
Miss Anastasiya Potapenko

IVV-07 Seeds from D90A homozygous ALS patients transmit motor neuron disease by initiating strain A and B aggregation
Miss Caitlin Henne

IVV-08 LRP4 over expression in muscle helps stabilize neuromuscular synapses in SOD1G83A ALS model mice.
Professor Peter Noakes

IVV-09 Doxycycline inhibits MMP-9 and inactivates microglia to preserve perineuronal nets in the SOD1G93A ALS mice.
Professor Peter Noakes

IVV-10 Targeting Osteopontin in ALS Neuroinflammation
Mr Jianing Lin

IVV-11 Gut Microbiota Dynamics in SOD1G93A Mice: Dysbiosis Patterns and FMT Intervention Effects
Ms Liru Wu

IVV-12 POSTER WITHDRAWN

IVV-13 Spatiotemporal Dysregulation of NK Cells in ALS Mice Reveals Early Gut Involvement and Progressive Multi-Tissue Dysfunction
Wenhua Deng

IVV-14 Characterization of SOD-1-, TDP-43 (TAR6/6) - and induced TDP43 ALS mouse models using Neurofilament Light Chain and other biomarkers
Dr Stefan Ebner-Benke

IVV-15 Characterization of an inducible intrathecal TDP43-AAV ALS model
Dr Stefan Ebner-Benke

IVV-16 Treatment with a cell-penetrating antibody targeting pTDP43 reduces intraneuronal pathology in a mouse model of ALS
Mr Ian Gallager

IVV-17 rNLS8 Mouse Model Exhibits Clinically Relevant Electrophysiological Changes Mirroring ALS Progression
Dr Stavroula Tsitkanou

IVV-18 Neuronal TDP-43 regulates myelin formation through neurexin 1 mRNA stabilization
Mr Yohei Iguchi

IVV-19 A synaptophagic microglia subtype perturbs motor circuits in Amyotrophic Lateral Sclerosis
Dr Greta Limoni

IVV-20 MYC-Driven Gliosis Impairs Neuron-Glia Communication in Amyotrophic Lateral Sclerosis
Dr Manuela Basso

IVV-21 Presymptomatic gene expression changes in motor neurons in a large animal model of motor neuron degeneration
Professor Stephen Kolb

IVV-22 Histopathologic Evaluation, Including Muscle Spindle and Neuromuscular Junction Integrity, in Pelvic Limb Muscle of a Canine Model of ALS
Dr Brandie Morgan-jack

IVV-23 Standardized cannabinoid–flavonoid blend CNR-401: brain penetration, bioavailability, and ALS disease-modifying activity across various animal model species
Mr Akeem Gardner

THEME 05

Human Cell Biology and Pathology (including iPSC studies)

HCB-01 A cliniconeuropathological study of lateral sclerosis in ALS
Dr Fei Song

HCB-02 Fe, Cu, and Zn Driven Pathologies in Human Primary Motor Cortex of ALS Patients
Mr Kevin Cornell

HCB-03 "Misfolded SOD1 in Sporadic and Familial ALS: New insights from our Nordic ALS Biobank"
Mrs Karin Maria Eleonor Forsberg

HCB-04 Matrin 3 Pathology in Cortical and Subcortical Regions in ALS and Dementias
Dr David Medina

HCB-05 Dissection of the ALS Motor Cortex and Identification of Individual L5 Extratelencephalic Neurons with Single-Cell Spatial Transcriptomics
Dr Frank Diaz

HCB-06 TDP-43 pathobiology is associated with lower neuronal Stathmin-2 expression in FTLD-MND-TDP: insights from highly multiplexed immunofluorescence
Ms Elizabeth Beutter

HCB-07 STMN2 and STMN3 cooperatively regulate mitochondrial genes expression at the transcription level, with the membrane-binding domain being essential
Dr Xiang Deng

HCB-08 Inhibition of Geranylgeranylation Restores Stathmin-2 Expression in TDP-43 Deficient Cells and Promotes Neurite Outgrowth
Dr Matthew Nolan

HCB-09 Increased Axonal TDP-43 Frequency and Decreased Axon Density in the Spinal Cord Point to Extensive Axonal Compromise in ALS Patients
Mr Alex Meng

HCB-10 Intramusucular nerve bundles reflect TDP-43 pathology in the medulla and spinal cord of ALS patients
Dr Takashi Kurashige

HCB-11 Decoding pathophysiology of amyotrophic lateral sclerosis based on physiological multimerization of TDP-43
Dr Kotaro Oiwa

HCB-12 Multiple motor proteins regulate the ALS-linked TDP-43 anterograde transport
Dr Monica Feole

HCB-13 Combined oxidative and optogenetic stress to model TDP-43 pathology in mutant patient motor neurons
Mr Benjamin Wymann

HCB-14 TBK1 alleviates TDP-43 pathology via the IFNβ-immunoproteasome pathway
Mr Shohei Sakai

HCB-15 Development of tissue-specific iPSC-derived models to investigate TDP-43-associated Amyotrophic Lateral Sclerosis (ALS)
Mr Andrea D'Angelo

HCB-16 Characterisation of the role of iPSC-derived microglia with TARDBP mutations in ALS
Ms Lara Nikel

HCB-17 ALS-related R155H p97 mutation disrupts lysosome quality control in iPSC-derived motor neurons
Ms Ivy Gao

HCB-18 A Robust Workflow for Cryopreservation of iPSC-Derived Motor Neurons and Optimized Expansion of Motor Neuron Progenitors for Disease Modeling
Ms Swetha Gurumurthy

HCB-19 Neurodevelopmental disruptions by C9orf72 expansion and TDP-43 mislocalization in ALS
Miss Orjona Stella Taso

HCB-20 The role of TDP-43-associated cryptic exon in KARLN in C9orf72-mediated cortical neurodegeneration
Dr Lauren Gittings

HCB-21 Dipeptide repeat proteins arising from the C9orf72 repeat expansion disrupt purine metabolism via adenosine deaminase in ALS
Dr Benjamin Hall

HCB-22 Mutant GGGGCC RNA prevents Yin Yang 1 from binding to Fuzzy promoter which stimulates Wnt/β-catenin pathway in C9ALS/FTD
Dr Stephen Chen

HCB-23 Ribosome-programmed frameshifting drives the production of chimeric dipeptide repeat proteins that amplify cytotoxicity in C9ORF72-ALS/FTD cell models
Dr Ya-Hui Lin

HCB-24 Contribution of astrocytic Sparcl1 to cortical synaptic dysfunction in C9orf72-FTD/ALS
Dr Robert Culibrk

HCB-25 Spatially resolved deep phenotyping of FTD-ALS via multiplexed immunofluorescence (mxIF)
Dr Yinyan Xu

HCB-26 Optical Pooled Screens identify activation of NRF2 as a novel therapeutic target in ALS/FTD
Dr Su Min Lim

HCB-27 Development of a 3D iPSC-Derived Corticospinal-Neuromuscular Assembloid Model for C9orf72-ALS
Dr Pierluigi Di Vinci

HCB-28 Generation of Fluid Dynamics-Based Spinal Cord Organoids toward Cell Therapy
Dr Suong Ngoc Anh Dang

HCB-29 Disrupting Pathogenic RNA Structures with a Novel ASO: Toward a Mechanism-Based Therapy for Sporadic ALS
Tatsuo Ito

HCB-30 M102, an NRF2 and HSF1 dual activator, recovers iAstrocyte toxicity in sporadic ALS
Dr Katie Bowden

HCB-31 Human Macrophage Responses to Chlorovirus ATCV-1 or its Capsid Protein Glycan, Depend upon Macrophage Polarization Phenotype
Dr Gary Pattee

HCB-32 Characterizing the pathological significance of WWOX loss and mutation in amyotrophic lateral sclerosis.
Dr Tiziana Petrozziello

THEME 06
Tissue Biomarkers

BIO-01 The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS)
Mr Elio Peraza

BIO-02 Access to ALS and FTD biofluid and cell lines via NINDS-supported biospecimen repositories: BioSEND and NHCDR
Dr Rebecca Price

BIO-03 Target ALS Multi-Center Human Postmortem Tissue Core
Ms Marina Selenica

BIO-04 Plasma and CSF benchmark and exploratory biomarkers in an Italian prospective longitudinal multicentric study: what should we use to untangle ALS heterogeneity?
Dr Manuela Basso

BIO-05 Rate of Change of Neurofilament Light Chain in the Answer ALS Cohort
Dr Jianing Wang

BIO-06 POSTER WITHDRAWN

BIO-07 Proteomic Analysis Reveals Prognostic Significance of Endocytosis and Exocytosis Related Proteins
Dr Munetaka Yamamoto

BIO-08 Biomarker discovery in the tear fluid of ALS patients using ultra-sensitive NUcleic acid Linked Immuno-Sandwich Assay (NULISA)
Dr Antonia F. Demleitner

BIO-09 Mapping the biochemical composition of sweat glands from presymptomatic ALS skin using Raman spectroscopy
Dr Katie Hanna

BIO-10 Cholesterol metabolism and esterification on CSF and plasma in ALS: preliminary results from the CHOL-ALS study
Dr Matteo Farè

BIO-11 Platelet Proteomics to Identify Novel Biomarkers and Mechanistic Insights in ALS
Dr Lathika Gopalakrishnan

BIO-12 Synaptic Phosphoproteome Reveals Divergent Signatures in ALS and FTD
Dr Lathika Gopalakrishnan

BIO-13 Exploration of synaptic pathology in ALS using CSF synaptic biomarkers in combination with known biomarkers of ALS
Ms Shreyasee Das

BIO-14 Neuropathological Characterizations of Sigma-1 Receptors in ALS: Enriched Post-synaptic Cisterns in Soma Specific to Lower Motor Neurons and Reduced Independent of TDP-43 Pathology
Dr Gulshan Yunisova

BIO-15 Reduction of Sigma-1 Receptor-Enriched Subsurface Cisterns in ALS Lower Motor Neurons Correlates with Neuronal Size and Structural Features
Dr Gulshan Yunisova

BIO-16 miRNA Biomarker Differentiates ALS from other Neurological Diseases
Professor Sandra Banack

BIO-17 Precision matters: why quality control is key in miRNA diagnostics for ALS.
Dr Rachael Dunlop

BIO-18 RNA Dysregulation as a Blood Biomarker of ALS
Dr Hristelina Ilieva

BIO-19 Ex-Vivo Validation of a Fluorescent Clinical Retinal Tracer to Detect TDP-43 in ALS patients With Applications in FTD and LATE
Dr Alex Huang

BIO-20 Optimization of TDP-43 Seed Amplification Assay for ALS and FTD
Dr Ganesh M Mohite

BIO-21 Investigating Exosomes and Human Endogenous Retroviruses as Emerging Biomarkers in Amyotrophic Lateral Sclerosis: Parallel Quantification and Comparative Analysis with Neurofilament Light Chain to Enhance Biomarker-Based Patient Stratification Strategies
Prof. Alfredo Iacoangeli

BIO-22 Predicting ALS survival using combined ALSFRS-R slope and NfL: insights from the ALS/MND Natural History Consortium's data and biofluid collection study
Mr Andres Arguedas

BIO-23 Serum cardiac Troponin T levels as a therapy response marker in Tofersen treated ALS
Dr Patrick Weydt

BIO-24 Exploratory Post Hoc Analysis of Neutrophil-to-Lymphocyte Ratio as a Novel Responsiveness Biomarker for Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis vs Untreated Propensity Score–Matched PRO-ACT Historical Placebo Controls
Mr Manabu Hirai

BIO-25 Sphingosine-1-Phosphate Decline as a Marker of Disease Progression in Korean Patients with Spinal and Bulbar Muscular Atrophy
Dr Jin-Sung Park

BIO-26 Explainable Deep Learning Framework for ALS and Cognitive Subtype Diagnosis with Region-of-Interest Validation
Dr Marta Vallejo

BIO-27 Proteomic profiling of cerebrospinal fluid-derived extracellular vesicles in ALS and asymptomatic C9orf72 HRE carriers
Dr Elizabeth Dellar

BIO-28 Investigating DNA Ligase III as a Potential Blood-Based Biomarker in ALS
Mrs Shashi Gautam

THEME 07
Pre-clinical Therapeutic Strategies

TST-01 Neuron-selective delivery of oligonucleotides via synaptic vesicle recycling: A strategy to bypass the CNS barrier and optimize intracellular exposure
Dr Nori Yumoto

TST-02 SOD1-targeting ASO delivery using low intensity pulsed ultrasound (LIPU)/microbubble mediated blood brain barrier opening: a new opportunity for patients with ALS
Dr Pierre De Rossi

TST-03 Next-generation capsids reveal efficient CNS targeting in C9orf72 FVB/NJ and C57BL/6 mouse strains, critical for gene therapy
Miss Ashley Dawson

TST-04 Intracerebroventricular administration of AAV9-Synapsin Caveolin-1 has the potential broader benefit for the treatment of ALS mice model
Dr Noriyuki Watanabe

TST-05 Preliminary Biodistribution of a Phosphorodiamidate Morpholino Oligomer at High Doses in the Mouse Central Nervous System
Dr Ianthe Pitout

TST-06 Allele-specific suppression of C9orf72 hexanucleotide expansions using CRISPRi for ALS therapy.
Miss Benisa Zogu

TST-07 Therapeutic Potential of Base Editing-Mediated Gene Therapy for Hereditary Motor Neuron Disease
Dr Keiko Imamura

TST-08 Assessment of an UNC13A cryptic exon skipping antisense oligonucleotide on restoring neuronal activity in iPSC-derived neuron models
Ms Stacee Mendonca

TST-09 An RNA Editing Approach Targeting Aberrant TDP-43 to Reduce its Mis-localization and Aggregation
Dr Leah Liu

TST-10 Assessment of SYF2 antisense oligonucleotides in an exploratory toxicity study
Mr Joscany Perez

TST-11 POSTER WITHDRAWN

TST-12 Phenotypic Drug Screening in Human iPSC-Derived Neurons Identifies Modifiers of Dipeptide Repeat-Induced Toxicity and TDP-43 Pathology in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
Dr Christine Marques

TST-13 Discovery and characterization of a novel Mitochondrial Permeability Transition Pore inhibitor in preclinical models of ALS
Dr Rupert Sandbrink

TST-14 Discovery of novel hyperphosphorylation sites in familial SOD1 ALS model correlating with the efficacy of novel Borsantrazole, a novel edaravone analogue
Mr Nitesh Sanghai

TST-15 GV1001, a tertomotide-derived peptide, alleviates motor dysfunction and extends survival in ALS (SOD1-G93A) transgenic mice
Miss Minhee Jang

TST-16 Modulation Of Gut Microbiome By Antibiotic Affects Survival In SOD-1 ALS Mice
Ms Megha Kaul

TST-17 Clopidogrel, a P2Y12 antagonist, prevents NMJ degeneration, slows disease progression, and extends lifespan of SOD1G93A mice
Ms Emma Suneby

TST-18 Pridopidine exerts neuroprotective effects through the activation of the Sigma-1 receptor (S1R) by modulating ER stress in iPSC-derived neural progenitor cells
Dr Bernd-Jan Sanson

TST-19 An oral drug against decline in the autophagy lysosomal pathway (ALP) and systemic inflammation, two "hallmarks" of ALS/FTD
Dr Knut M. Wittkowski

TST-20 Developing an ALS Therapy using Engineered Human CAR Tregs with Enhanced Disease-Modifying Activity
Dr David Graber

TST-21 Inhibitory synapses represent a therapeutic mechanism for human spinal stem cells in ALS
Mr Kyle Loi

TST-22 hsa-miR-937-5p in serum extracellular vesicles as a therapeutic target for amyotrophic lateral sclerosis
Dr Daisuke Ito

TST-23 Selection of DNA Aptamers for TDP-43 to Inhibit Protein Aggregation in ALS
Mr Daniel Knight

TST-24 POSTER WITHDRAWN

TST-25 Expression of fatty acid binding protein 4 and potassium channel Kv1.3 in microglia isolated from SOD1G93A and C9-BAC mouse brain and spinal cord
Miss Amelia Miklavec

TST-26 Targeting Type I PRMTs in ALS: In Vivo Evaluation of MS023 and GSK3368715 in TDP43Q331K and SOD1G93A Mice
Ms Kaly Mueller

TST-27 Developing CCDC146 as a Broad Spectrum ALS Therapeutic
Miss Connie Treanor

TST-28 CNS-Specific Disruption of Neuregulin Signaling Modulates ALS Progression
Dr Fei Song

TST-29 Harnessing Light: Developing a Targeted Optogenetic Treatment for Bulbar ALS Symptoms
Miss Apaala Basak

TST-30 Evaluation of Maximum Insufflation Capacity Technique in Amyotrophic Lateral Sclerosis Patients
Dr Sergio Mateus

TST-31 Multi-site Anodal Direct Current Stimulation Preserves Motor Function and Modulates Key Cellular Pathways in TDP-43 and SOD1 Mouse Models of ALS
Professor Zaghloul Ahmed

TST-32 Evaluation of Cough Efficacy and its Correlation with Respiratory Pressures in Individuals with Amyotrophic Lateral Sclerosis
Dr Rafael Oliveira

THEME 08
Clinical Imaging and Electrophysiology

IMG-01 Gut bile acid metabolism may contribute to ALS-related cognitive impairment through structural brain alterations
Ms Zehui Li

IMG-02 Pioneering In-Vivo Metabolic Imaging in ALS Using Hyperpolarized [1-^{13}C] Pyruvate MRI
Dr Mia Heintzelmann

IMG-03 Beyond the Brain: Tongue MRI Radiomics as a Novel Biomarker in Amyotrophic Lateral Sclerosis
Mr Essa Madkhali

IMG-04 Novel low-field imaging modalities highlight the potential for early detection of MND
Dr Holly Spence

IMG-05 Correlation of Quantitative Susceptibility Mapping with Upper Motor Neuron Dysfunction, Motor Function, and Demographics in Patients with PLS and ALS
Ms Sophia Mostowy

IMG-06 Creatine Kinase but not Troponin T predicts dysautonomia measured by heart rate variability in ALS patients
Dr Alexander Juto

IMG-07 A potential link between neural oscillation alterations and motor symptoms of ALS: A MEG study
Mr Christian Steenkjaer

IMG-08 Identifying the Epicenters of Brain Disease in Patients with Classic ALS and ALS-FTD: A Multimodal Imaging Study
Professor Erik Pioro

THEME 09
Clinical Trials and Trial Design

CLT-01 The NEALS Consortium: Thirty Years of Advancing Amyotrophic Lateral Sclerosis (ALS) Research through Collaboration and Innovation
Ms Christina Smith

CLT-02 Dual Coordination Centers role in ALL ALS Consortium: A Success Story, Not Too Many Cooks in the Kitchen
Mrs Courtney Igne

CLT-03 Target ALS Global Natural History Study in a Global ALS Population
Ms Amy Easton

CLT-04 PREVENT ALL ALS: Design of a national ALS gene carrier natural history study
Dr Mark Garret

CLT-05 Design and Operationalization of the PREVENT ALL ALS Genetic Testing Sub-Study
Ms Mohini Vaidya

CLT-06 Platform Trial Design to Evaluate Riluzole as a Neuroprotectant in Canine Degenerative Myelopathy
Professor Joan Coates

CLT-07 Accelerating discovery in ALS: the HEALEY ALS Platform Trial's Perpetual Data Sharing Plan
Ms Lindsay Heyd

CLT-08 POSTER WITHDRAWN

CLT-09 Design of the Multiple Ascending Dose (MAD) trial of UNC13A splice modulating ASO LY4256984 in patients with sporadic Amyotrophic Lateral Sclerosis (ALS).
Dr Alexander Brandt

CLT-10 FUNCtion ALS: A Phase 1/2 trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of TRCN-1023, an antisense oligonucleotide restoring UNC13A, in adult persons with ALS
Dr Irina Antonijevic

CLT-11 PRO-101: study design and interim results from a hybrid Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in participants with ALS
Ms Erin Fleming

CLT-12 EPISOD1: A Phase 1/2, Multicenter Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Patients with SOD1 ALS (SOD1-ALS)
Dr Marija Jovanovic

CLT-13 Interim results from GOALS, a phase 1b trial of ALN-SOD, an intrathecally-administered small interfering RNA targeting SOD1, in symptomatic SOD1-ALS
Dr Angela Genge

CLT-14 A Phase 1, Multicenter, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in ALS (LUMINA)
Dr Sabrina Paganoni

CLT-15 QRL-101 – Phase1 studies evaluating safety and pharmacodynamics of a KCNQ2/3 modulator in healthy volunteers & next steps for development in ALS
Emma Bowden

CLT-16 ANQUR, the First-in-Human Phase 1 study of QRL-201 in ALS Advances to Dose-Range Finding using a Novel Population Pharmacokinetic Analysis
Emma Bowden

CLT-17 Clinical Development of LTX-002, an ASO for the treatment for ALS
Dr Lawrence Severt

CLT-18 Non-clinical development and Phase 1/ 2 clinical trial design of VTx-002, an AAV5.2 vectorized intrabody targeting TDP-43 for Amyotrophic Lateral Sclerosis
Dr Olga Uspenskaya

CLT-19 ALT001, protein complex derived from stimulated stem cells, a novel neural repair reagent from bench to clinic
Mrs Fengfei Huang

CLT-20 The development of AMBROXOL in ALS/MND
Professor Michael Spedding

CLT-21 COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics
Dr Kazuko Matsuda

CLT-22 A study to evaluate the efficacy and safety of VHB937 in people with ALS: Interim baseline data from the ASTRALS double-blind, randomized, placebo-controlled study
Dr Ram Miller

CLT-23 A Planned Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with ALS
Dr Leonard van den Berg

CLT-24 Compassionate Use of C9ORF72 targeted ASOs in ALS – Experience from eight patients at three German Centers
Dr Patrick Weydt

CLT-25 Interim Results Confirm the Safety and Feasibility of Autologous Hybrid TREG/Th2 T Stem Cells (RAPA-501) in ALS Patients With Severe Respiratory Insufficiency
Dr James Berry

CLT-26 Clinical Safety of ultra-high-dose methylcobalamin in patients with Amyotrophic Lateral Sclerosis: Open-label extension of a phase II/III randomized controlled trial
Dr Takayuki Ishida

CLT-27 Long-term efficacy of ultra-high-dose methylcobalamin in Amyotrophic Lateral Sclerosis: Phase II/III trial and open-label extension
Professor Yuishin Izumi

CLT-28 Long-term outcomes of JETALS (Japan Early-stage Trial of ultra-high dose methylcobalamin for ALS) Study: Effects of serum homocysteine levels on survivals in ALS patients
Professor Ryuji Kaji

CLT-29 Time To Loss Of 15% Predicted Vital Capacity and Survival Favors NP001 Over Placebo in Two ALS Trials
Professor Namita Goyal

CLT-30 Cell free miRNAs are pharmacodynamic biomarkers for enhanced Dicer activity by Enoxacin in human patients with Amyotrophic lateral sclerosis
Dr Iddo Magen

CLT-31 Enhancing Plasma NfL Prognostic Value and Improving Trial Efficiency through Digital Twins in ALS
Hanalei Pham

CLT-32 The Standardized ALSFRS-R at Home Consortium: Proposal for development, validation, and adoption of an integrated, self-administered ALSFRS-R
Dr Matti Allen

CLT-33 Voice Recording Adherence in ALS: A Comparison of In-Clinic and At-Home Assessments
Dr Brittney Harkey

CLT-34 Evaluating the Precision of Quantitative Voice Characteristics as Endpoints in ALS Clinical Trials
Dr. Saloni Sharma

CLT-35 At-Home Telespirometry Identifies Significantly Slower Decline of ALS Functional Rating Scale-Revised Total Score but not Erect/Supine Slow Vital Capacity in Edaravone-Treated ALS Subjects Not Requiring Non-Invasive Ventilation [NCT05106569]
Dr. Eufrosina I. Young

CLT-36 Smartphone Application–Mediated, Supervised, At-Home Telespirometry Identifies Statistically Significant Differences in Erect and Supine Slow Vital Capacity and ALSFRS-R Decline as a Function of Non-invasive Ventilation Treatment Status in Multicenter, Prospective, Longitudinal, Observational Clinical Study [NCT05106569]
Dr. Eufrosina I. Young

CLT-37 Leveraging Integrated Digital Infrastructure to Modernize Remote-Enabled ALS Research: Lessons from the ALL ALS study
Dr Praveena Mohan

CLT-38 A Scalable People-Facing Platform and Models for Decentralized Observational Research and Validation of Digital Biomarkers in People Living with ALS/MND
Mr Alex Sherman

CLT-39 Leveraging External Controls from PRO-ACT for Exploratory Efficacy Assessment in Early-Phase ALS Trials
Dr Melanie Quintana

CLT-40 Engaging Diverse Voices, Shaping Trials: Integrating Patients and Caregivers into ALS Clinical Trial Design
Mrs Megan Baierlein

CLT-41 Global Patient Engagement in All Stages of ALS Research: Fostering Patient-Researcher Partnerships for Impact
Dr Nadia Sethi

CLT-42 Enhancing Enrollment in ALS Clinical Research: The Accelerated Centers of Enrollment (ACE) Initiative
Ms Michelle Redenz

CLT-43 A Comparison of Baseline Characteristics of Decentralized and In-Clinic Participants Enrolled in the CNM-Au8 EAP04 Study
Ms Abigail O'Connell

CLT-44 Frontotemporal Degeneration and Amyotrophic Lateral Sclerosis: Perspectives on Clinical Research
Dr Shana Dodge

THEME 10
Disease Stratification and Phenotyping of Patients

DSP-01 ASSESS ALL ALS: A longitudinal, multi-modal natural history study to characterize ALS disease progression using on-site and remote cohorts
Dr Robert Bowser

DSP-02 The ANSWER ALS Foundation: Advancing ALS Research Through Strategic Collaboration and Innovation
Ms Tara Lincoln

DSP-03 Blood-CSF Brain Barrier Alterations in Fast-progressing and Slow-Progressing ALS
Dr Nadine Bakkar

DSP-04 A Nutritional Biomarker-Based Composite Score (PRO-MAL score) for Prognostic Stratification in Amyotrophic Lateral Sclerosis: Development and Clinical Application
Dr Federica Cerri

DSP-05 Characterization of cardiovascular disease, non-motor symptoms and biomarkers in a Northern Swedish cohort of spinobulbar muscular atrophy.
Dr Anna-Karin Roos

DSP-06 Investigation of olfactory dysfunction in presymptomatic and early ALS: A premodiALS study
Dr Laura Tzeplaeff

DSP-07 Diagnostic Delay Leads to Inpatient ALS Diagnoses: A Case Series
Dr Ryan Donaghy

DSP-08 Dyspnea, forced vital capacity, and noninvasive ventilation initiation thresholds in patients with Amyotrophic Lateral Sclerosis.
Dr Andrew Graustein

DSP-09 Predicting Enteral Nutrition Requirement in Patients with Amyotrophic Lateral Sclerosis via a Machine Learning Model Using Single-Timepoint Clinical Data
Mr Noritaka Wakasugi

DSP-10 Divergence in FUS-ALS: Neurocognition, glucose metabolism and mutation variant distinguish severe juvenile-onset from adult-onset cases
Dr Alexandra Jürs

DSP-11 C9orf72-bvFTD despite little or no TDP-43 pathology in relevant brain regions
Dr Sevinc Jakab

DSP-12 Rationale for digital health technology assessments in FUNCtion ALS, a Phase 1/2 trial of TRCN-1023, an antisense oligonucleotide restoring UNC13A, in adult persons with Amyotrophic Lateral Sclerosis
Dr Sanjay Chandriani

DSP-13 Actigraphy in ALS: Patient Perspectives on Feasibility and Acceptability as Patient-Centric Outcome Measures
Dr Nadia Sethi

THEME 11
Cognitive and Psychological Assessment and Support

COG-01 ANXA11 Variants Define a Distinct ALS Phenotype with Cognitive Involvement
Professor Adriano Chio

COG-02 What a Simple Story Can Reveal: Correlating Discourse and Cognitive Profiles in Individuals with ALS.
Professor Liziane Bouvier

COG-03 Self-reported initiation apathy is related to poor quality of life in ALS
Dr Ratko Radakovic

COG-04 Patient-relevant measurement in amyotrophic lateral sclerosis: a mixed-methods study of selected clinical outcome assessments
Mr William B. Nowell

COG-05 Exploring Social Determinants of Health in people with ALS
Dr Saloni Sharma

COG-06 In person connection with others impacted by inherited ALS and FTD is a need for the genetic ALS and FTD community.
Cassandra Haddad

COG-07 Families with MND as partners: Developing a joint approach to clinical discussions and education for cognitive and behavioural changes in MND
Dr Rebecca Francis

COG-08 Co-Designing Educational Resources for Cognitive and Behavioural Changes in Motor Neurone Disease: A Lived Experience Informed Approach
Dr Rebecca Francis

THEME 12
Clinical Management and Support

CMS-01 Engaging with clinical treatment decisions in ALS: a scoping review
Ms Jennifer Bedford

CMS-02 A French national network to improve organization and inclusion in clinical trials : Alliance on Clinical Trials for ALS-MND (ACT4ALS-MND)
Professor Gaelle Bruneteau

CMS-03 Caring for the Homebound Patient with ALS
Dr Keelie Denson

CMS-04 A Study on the Effects of Prior Use of Non-Invasive Ventilation (NIV) in ALS Patients Receiving Tracheostomy with Invasive Ventilation (TIV) Care
Ms Yuki Nakayama

CMS-05 Non-Invasive Ventilation Support During Gastrostomy insertion in Motor Neuron Disease: A Retrospective Analysis
Dr Abdisamad Ali

CMS-06 Evaluating Adherence to the 'Nutrition and Gastrostomy' section of the NICE Guidelines in Motor Neurone Disease (MND) Care: A Retrospective Clinical Audit at University College London Hospitals (UCLH)
Mrs Justyna Reinert

CMS-07 A Retrospective Case Note Audit of the Nutritional Status of Patients with Motor Neurone Disease referred to Dietetic service at a Tertiary Hospital and UK MND Care Centre
Mrs Justyna Reinert

CMS-08 Prevalence and Clinical Features of Bullous Pemphigoid in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Study of 1,067 Cases
Dr Kota Bokuda

CMS-09 Self-reported symptom burden in amyotrophic lateral sclerosis in reference to the ALS Functional Rating Scale - results of a large multicenter study
Dr André Maier

CMS-10 The Delta FVC: A potential clinical outcome measure to predict rate of ALS progression
Dr Kelly Gwathmey

CMS-11 Functional Impairment at the end of Life in ALS – A systematic Analysis of ALSFRS-R data.
Dr Susanne Spittel

CMS-12 Assessment of manual function in amyotrophic lateral sclerosis (ALS) with the ALS Pen: Advancement of the device and implementation of a follow-up feasibility study
Mr Alessio Riitano

CMS-13 The ALS App – a smartphone application for ALS monitoring, patient engagement, and data collection – data analysis 5 years after launch
Mr Senthil Kumar Subramanian

CMS-14 A Web-based Survey on Lower Urinary Tract Symptoms in Amyotrophic Lateral Sclerosis
Mr Gabriel Jacobs

CMS-15 Advancing ALS/MND Education in Undergraduate and Graduate Training Programs for Psychology Professionals in Japan: Current Status and Future Perspectives
Dr Yuji Tanaka

CMS-16 Difficult Conversations in ALS/MND
Mrs Jill Brattain

CMS-17 Sustaining Life Through Speech as a Tool: Strategies for Sustaining Life and Communication in ALS
Yui Hasegawa

CMS-18 Enhancing Quality Of Life Through Insights Based On The ALS/MND Personal Needs Matrix
Prof. Jarnail Chudge

CMS-19 Mapping the landscape of behavioural symptoms in MND: A comprehensive scoping review on clinical presentation and assessments.
Dr Ana Paula Trucco

CMS-20 ALSUntangled Program
Dr Xiaoyan Li

CMS-21 Medically Assisted Death in a center of reference in Colombia: A cohort of ALS patients
Dr Martha Peña Preciado

WIP
Work in Progress

BM-01 Characterising Clinical Patterns and Progression in Motor Neurone Disease Using Structured and Unstructured EHR Data: A Retrospective Cohort Study with NLP and Unsupervised Clustering
Mr Yusuf Abdulle

BM-02 Functional characterization of computationally-discovered novel risk genes of Amyotrophic Lateral Sclerosis
Miss Mira Antonopoulos

BM-03 Epigenome wide association study for diagnostic delay in amyotrophic lateral sclerosis
Miss Johanna Kristiina Vallikivi

BM-04 Defining Glymphatic and Neurovascular Regulatory Networks in ALS via Single-Nucleus Multi-Omics
Mr Joseph Guidubaldi

BM-05 Characterizing Microbial Markers Predictive for ALS Onset and Progression
Mrs Hannah George

BM-06 Characterising the Metagenomic Landscape of Amyotrophic Lateral Sclerosis from Unmapped Whole Genome Sequencing Data
Mr Renato Santos

BM-07 A cross-sectional study of the gut microbiome and systemic inflammation in ALS.
Mr Renato Santos

BM-08 Exploring Immune Dysregulation and Disease Mechanisms in ALS4 with SetX Mouse Models.
Mr Renato Santos

BM-09 Electrophysiological characterization of neocortical neurons' excitability in a mouse model of ALS at different stages of the disease
Dr Reem Debian

BM-10 Modeling C9ORF72 Haploinsufficiency in ALS: A Murine Model of G4C2 Repeat Expansion
Ms Maanya Dixit

BM-11 Modelling FUS-R495X-Associated ALS using iPSC-Derived Human Motor Neurons to study gain of toxicity mechanisms
Miss Jieni Wang

BM-12 ALS may be a disease arising from human evolution involving gangliosides and lactate: therapeutic opportunities
Professor Michael Spedding

BM-13 The Robert Packard Center for ALS Research: 25 Years of Funding Global Collaborative Pre-Clinical Research
Mrs Suzanne Connelly

BM-14 Wearable Ultrasound and AI-Based Fasciculation Detection for Early ALS Diagnosis: Feasibility and Exploratory Trial Design
Dr Chizu Saeki

BM-15 Wearable Sensor-Derived Digital Outcomes for Quantifying Gait in ALS
Dr Katherine Burke

BM-16 Digitize ALS: Methodology for a Wearable Digital Sensor Sub-Study in the ALL ALS Consortium
Dr Katherine Burke

BM-17 CAPTURE ALS: Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Dr Angela Genge

BM-18 Global Taskforce on Genetic Counselling and Testing in ALS/MND: Developing Consensus-Based Guidelines
Dr Martina De Majo

BM-19 Evaluation of Long-Term Prognosis of Edaravone in ALS Patients: A Real-World Comparative Study Using SUNRISE Japan and JaCALS Registry Data
Mr Manabu Hirai

BM-20 Toward Comprehensive Remote Assessment of ALS Patients: Combining Objective Digital Measures with Patient Reports of Problems
David Suendermann-Oeft

BM-21 Understanding dynamics of ALS disease progression through free-living monitoring of gait using wearable accelerometers
Dr Marcin Straczkiewicz

BM-22 IsomiR Utility in ALS Prognostication
Dr Iddo Magen

CP-01 ALS-Net Chile: Building a National Network for Equitable ALS Care
Mrs Natalia Hofmann

CP-02 Italy's first international ALS online seminar series: SLA in Chiaro by Associazione conSLAncio Onlus
Dr Tiziana Petrozziello

CP-03 A Subsidiary Framework for ALS
Miss Mara Rold

CP-04 Accessible Beaches for Tracheostomized ALS Patients
Miss Mara Rold

CP-05 Tofersen-associated Radiculitis in SOD1-ALS Effectively Managed with IV but not IT Corticosteroid Administration
Dr. Stephen Johnson

CP-06 The impact of aquatics on the quality of life for people with amyotrophic lateral sclerosis
Dr Brianna Barcelo

CP-07 The application of exercise to enhance quality of life for people with amyotrophic lateral sclerosis
Dr Theresa Stettner

CP-08 Adapted Cuisine for ALS Dysphagia
Miss Vittoria Zuccaro

CP-09 Training Family Care Assistants in ALS
Miss Vittoria Zuccaro

CP-10 The Healing Power of Ethical Language
Sig.ra Grazia Micarelli

CP-11 Innovating ALS Care Delivery
Sig.ra Grazia Micarelli

CP-12 Exploring Palliative Care Needs in Amyotrophic Lateral Sclerosis. Perspectives from Patients and Caregivers: A Scoping Review.
Dr Erica Scirocco

CP-13 Feasibility and Clinical Utility of Patient-Reported Outcome Measures in Primary Lateral Sclerosis
Dr Erica Scirocco

CP-14 Enriching Clinical Data with AI-Powered Document Processing
Mrs Julia Geller

THURSDAY 4 DECEMBER

08.30 – 12.30	**WFN ALS/MND Specialty Group** Britannia/Cambria	First Floor
13.00 – 16.30	**ALL ALS Consortium** Britannia/Cambria	First Floor
15.00 – 18.00	**ALS App Europe Initiative Meeting** Aurora	First Floor
17.00 – 19.00	**Project MinE** *(closed meeting)* Britannia/Cambria	First Floor
16.00 – 18.00	**Registration International Symposium** Atrium	Ground Floor
18.00 – 19.30	**Welcome Networking Reception** Commodore	Ground Floor

FRIDAY 5 DECEMBER

07.00 – 18.00	**Registration International Symposium** Atrium	Ground Floor
07.00 – 18.00	**Speaker Room** Sovereign	First Floor
08.30 – 10.00	**Symposium Joint Opening Session** Commodore A-D	Ground Floor
10.00 – 10.30	**Refreshments and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
10.00 – 10.30	**Exhibitors** Commodore Foyer	Ground Floor
10.30 – 12.30	**Symposium Biomedical Session 2A** Commodore A-D	Ground Floor
10.30 – 12.30	**Symposium Clinical Session 2B** Constellation	First Floor
12.30 – 14.00	**Lunch and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
12.30 – 14.00	**Longitude Prize on ALS Partner Meeting** *(closed meeting)* Aurora	First Floor
14.00 – 15.30	**Symposium Biomedical Session 3A** Commodore A-D	Ground Floor
14.00 – 15.30	**Symposium Clinical Sessions 3B** Constellation	First Floor
15.30 – 16.00	**Refreshments and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
15.30 – 16.00	**Exhibitors** Commodore Foyer	Ground Floor
16.00 – 17.30	**Symposium Biomedical Session 4A** Commodore A-D	Ground Floor
16.00 – 17.30	**Symposium Clinical Session 4B** Constellation	First Floor
17.30 – 19.00	**Poster Session A** Bay Pavilion	Ground Floor

SATURDAY 6 DECEMBER

07.00 – 18.00	**Registration International Symposium** Atrium	Ground Floor
07.00 – 18.00	**Speaker Room** Sovereign	First Floor
08.30 – 10.00	**Symposium Biomedical Session 5A** Commodore A-D	Ground Floor
08.30 – 10.00	**Symposium Clinical Session 5B** Constellation	First Floor
08.30 – 10.00	**Symposium Alternative Session 5C** Commodore E	Ground Floor
10.00 – 10.30	**Refreshments and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
10.00 – 10.30	**Exhibitors** Commodore Foyer	Ground Floor
10.30 – 12.30	**Symposium Biomedical Session 6A** Commodore A-D	Ground Floor
10.30 – 12.30	**Symposium Clinical Session 6B** Constellation	First Floor
10.30 – 12.30	**Symposium Alternative Session 6C** Commodore E	Ground Floor
12.30 – 14.00	**Lunch and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
12.30 – 14.00	**NEALS Member Meeting** *(closed meeting)* Cambria	First Floor
14.00 – 15.30	**Symposium Biomedical Session 7A** Commodore A-D	Ground Floor
14.00 – 15.30	**Symposium Clinical Session 7B** Constellation	First Floor
14.00 – 15.30	**Symposium Alternative Session 7C** Commodore E	Ground Floor
15.30 – 16.00	**Refreshments and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
15.30 – 16.00	**Exhibitors** Commodore Foyer	Ground Floor
16.00 – 17.30	**Symposium Biomedical Session 8A** Commodore A-D	Ground Floor
16.00 – 17.30	**Symposium Clinical Session 8B** Constellation	First Floor
16.00 – 17.30	**Symposium Alternative Session 8C** Commodore E	Ground Floor
17.30 – 19.00	**Poster Session B** Bay Pavilion	Ground Floor

SUNDAY 7 DECEMBER

07.00 – 12.00	**Registration International Symposium** Atrium	Ground Floor
07.30 – 13.30	**Speaker Room** Sovereign	First Floor
08.30 – 10.00	**Poster Session C** Bay Pavilion	Ground Floor
10.00 – 10.30	**Refreshments, Networking and Exhibitors** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
10.00 – 10.30	**Exhibitors** Commodore Foyer	Ground Floor
10.30 – 12.30	**Symposium Clinical Sessions 9A** Commodore A-D	Ground Floor
10.30 – 12.30	**Symposium Biomedical Session 9B** Constellation	First Floor
10.30 – 12.30	**Symposium Alternative Session 9C** Commodore E	Ground Floor
12.30 – 13.30	**Lunch and Networking** Commodore Foyer and Terrace, Bay Terrace Constellation Foyer	Ground Floor First Floor
13.30 – 15.10	**Symposium Joint Closing Session** Commodore A-D	Ground Floor

Ground Floor



The MND Association is pleased to provide a complimentary evening shuttle bus service for Symposium delegates (see 'Important Information' below).

Buses will run on a continuous circular route:

- The departure point will be outside the main entrance of the Loews Coronado Bay Resort.
- The drop-off and return point will be Orange Street, in the centre of Coronado Village.

Shuttle Bus Information

First Bus Departs Loews Coronado Bay Resort Main Entrance			Final Bus Returns Orange Street Coronado Village		
Friday 5 December	Saturday 6 December	Sunday 7 December	Friday 5 December	Saturday 6 December	Sunday 7 December
19:00	**19:00**	**18:00**	**22:30**	**22:30**	**22:30**

Important Information

- Shuttle bus capacity is limited and provided on a 'first come, first served' basis.
- Delegates must show their Symposium badge when boarding.
- Due to space restrictions, large luggage items cannot be taken on board (bags must be small enough to remain with you in your seat).
- Unfortunately, it has not been possible to provide accessible buses. If you require accessible transport, please enquire at the Concierge Desk, situated in the hotel lobby. **Alternatively, Loews Coronado Bay Resort provides a wheelchair accessible daily shuttle service to/from Coronado Village from 09:00 to 21:00. This service runs every 30 minutes on the hour/half hour from the Loews Marina Office (next to the Bay Pavilion).**

Disclaimer

The organisers of the International Symposium on ALS/MND wish to remind all delegates that we cannot be held responsible for personal belongings left on coaches or for any delegates who miss the last coach returning to the venue each night. It is the responsibility of each delegate to ensure they arrive at the designated pick-up areas on time. We highly encourage all attendees to plan accordingly. Delegate cooperation is appreciated to ensure a pleasant experience for all.

Please visit our exhibitors, located online and in the Commodore Foyer

More information can be found on our website
www.symposium.mndassociation.org, and on the Symposium App

ALAMAR BIOSCIENCES

ALLALS
Access for ALL in ALS

ALS
THERAPY DEVELOPMENT
INSTITUTE

AXOL

Corcept
THERAPEUTICS

Evestia
Clinical

LifeArc

NEURALINK

NEUROSYS
CNS/PNS SERVICES

tobii dynavox

ferrer
for good

prilenia

INTERNATIONAL ALLIANCE
OF ALS/MND ASSOCIATIONS

ALS
ASSOCIATION

EXHIBITOR FLOORPLAN



2025 Sponsors

With grateful thanks to the following supporters of the
36th International Symposium on ALS/MND

AcuraStem

Corcept THERAPEUTICS

Cytokinetics

Evestia Clinical

ferrer for good

prilenia

Lilly A MEDICINE COMPANY

QurAlis™

REGENERON SCIENCE TO MEDICINE®

Mitsubishi Tanabe Pharma America

uniQure

mnda motor neurone disease association

37th international symposium on ALS/MND

AMSTERDAM 2026

Join us in Amsterdam, Netherlands

9 - 11 December 2026

Provisional abstract submission deadline:
Thursday 9 July 2026

Stay connected:

@mndresearch
#alsmndsymp

For further information please contact:

Motor Neurone Disease Association
Telephone: +44 (0) 1604 611837
Email: symposium@mndassociation.org
Email: abstracts@mndassociation.org

www.mndassociation.org
www.symposium.mndassociation.org

In cooperation with

ALS patiënten vereniging
ALS Centrum Nederland
ALS Stichting ALS Nederland